165 related articles for article (PubMed ID: 37761833)
1. TERTmonitor-qPCR Detection of
Brás JP; Jesus TT; Prazeres H; Lima J; Soares P; Vinagre J
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761833
[TBL] [Abstract][Full Text] [Related]
2. Establishment and Validation of the Detection of TERT Promoter Mutations by Human Gliomas U251 Cell Lines.
Bai H; Bai S; Li X; Zhang Y; Li Y; He F; Cheng W
Biomed Res Int; 2021; 2021():3271395. PubMed ID: 34159191
[TBL] [Abstract][Full Text] [Related]
3. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.
Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T;
Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients.
Qu CX; Ji HM; Shi XC; Bi H; Zhai LQ; Han DW
Brain Behav; 2020 Apr; 10(4):e01583. PubMed ID: 32146731
[TBL] [Abstract][Full Text] [Related]
5. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.
Batista R; Cruvinel-Carloni A; Vinagre J; Peixoto J; Catarino TA; Campanella NC; Menezes W; Becker AP; de Almeida GC; Matsushita MM; Clara C; Neder L; Viana-Pereira M; Honavar M; Castro L; Lopes JM; Carvalho B; Vaz RM; Máximo V; Soares P; Sobrinho-Simões M; Reis RM; Lima J
Int J Cancer; 2016 Jul; 139(2):414-23. PubMed ID: 26914704
[TBL] [Abstract][Full Text] [Related]
6. New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma.
Pierini T; Nardelli C; Lema Fernandez AG; Pierini V; Pellanera F; Nofrini V; Gorello P; Moretti M; Arniani S; Roti G; Giovenali P; Lupattelli M; Metro G; Molica C; Castrioto C; Corinaldesi R; Laurenti ME; Ascani S; Mecucci C; La Starza R
Acta Neuropathol Commun; 2020 Aug; 8(1):145. PubMed ID: 32843091
[TBL] [Abstract][Full Text] [Related]
7. IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas.
Duan WC; Wang L; Li K; Wang WW; Zhan YB; Zhang FJ; Yu B; Bai YH; Wang YM; Ji YC; Zhou JQ; Liu XZ; Zhang ZY
Medicine (Baltimore); 2018 Dec; 97(50):e13675. PubMed ID: 30558073
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
9. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
[TBL] [Abstract][Full Text] [Related]
11. Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations.
Otsuji K; Sasaki T; Tanabe M; Seto Y
Br J Cancer; 2021 Jan; 124(2):466-473. PubMed ID: 33046803
[TBL] [Abstract][Full Text] [Related]
12. Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy.
Cao W; Lan J; Hu C; Kong J; Xiang L; Zhang Z; Sun Y; Zeng Z; Lei S
Aging (Albany NY); 2024 Mar; 16(6):5618-5633. PubMed ID: 38499392
[TBL] [Abstract][Full Text] [Related]
13. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K
Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499
[TBL] [Abstract][Full Text] [Related]
14. Detection of IDH1 and TERT promoter mutations with droplet digital PCR in diffuse gliomas.
Ge J; Liu MY; Li L; Deng Q; Liu F; Luo Y; Wang L; Yao G; Zhu D; Lu H; Liang M; Deng S; Zhou R; Luo T
Int J Clin Exp Pathol; 2020; 13(2):230-238. PubMed ID: 32211103
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
[TBL] [Abstract][Full Text] [Related]
16. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.
Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770
[TBL] [Abstract][Full Text] [Related]
17. Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR.
Miki S; Satomi K; Ohno M; Matsushita Y; Kitahara M; Miyakita Y; Takahashi M; Matsuda M; Ishikawa E; Matsumura A; Yoshida A; Narita Y; Ichimura K
Brain Tumor Pathol; 2020 Oct; 37(4):154-158. PubMed ID: 32749624
[TBL] [Abstract][Full Text] [Related]
18. Identification of IDH and TERTp mutation status using
Ozturk-Isik E; Cengiz S; Ozcan A; Yakicier C; Ersen Danyeli A; Pamir MN; Özduman K; Dincer A
J Magn Reson Imaging; 2020 Jun; 51(6):1799-1809. PubMed ID: 31664773
[TBL] [Abstract][Full Text] [Related]
19. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.
Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH
Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427
[TBL] [Abstract][Full Text] [Related]
20. Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.
Izquierdo C; Barritault M; Poncet D; Cartalat S; Joubert B; Bruna J; Jouanneau E; Guyotat J; Vasiljevic A; Fenouil T; Berthezène Y; Honnorat J; Meyronet D; Ducray F
Neurosurgery; 2019 Sep; 85(3):E448-E456. PubMed ID: 30407589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]